Eight injectable drugs will require prior authorization

**Summary:** Effective June 1, 2018, Amerigroup will require prior authorization (PA) for eight injectable drugs.

Noncompliance with the new requirements may result in denied claims. PA requirements will be added to the following codes:

- J0565 — Injection, bezlotoxumab, 10 mg
- J1428 — Injection, eteplirsen, 10 mg
- J2326 — Injection, nusinersen, 0.1 mg
- J2350 — Injection, ocrelizumab, 1 mg
- J9022 — Injection, atezolizumab, 10 mg
- J9023 — Injection, avelumab, 10 mg
- J9285 — Injection, olaratumab, 10 mg
- Q2040 — Tisagenlecleucel

Please use one of the following methods to request PA:

- **Web:** [https://www.Availity.com](https://www.Availity.com)
- **Fax:** 1-800-964-3627
- **Phone:** 1-800-454-3730

Please refer to the Precertification Lookup Tool for detailed authorization requirements. Go to [https://providers.amerigroup.com](https://providers.amerigroup.com), select your state and select **Quick Tools/Precertification Lookup Tool** under **Provider Resources & Documents**.

Federal and state law, as well as state contract language including definitions and specific contract provisions/exclusions, take precedence over these prior authorization rules and must be considered first when determining coverage.

If you have questions about this communication or need assistance with any other item, call Provider Services at 1-800-454-3730.